Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
Top Page
Akums Drugs and Pharmaceuticals Limited
(AKUMS)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹506.00
▲(20.45% Upside)
Action:ReiteratedDate:12/18/25
The overall stock score for Akums Drugs and Pharmaceuticals Limited is driven primarily by strong financial performance, with notable revenue growth and improved profitability. However, technical indicators suggest a bearish trend, and the valuation is moderate without a dividend yield to attract income investors. The absence of earnings call insights and corporate events did not impact the score.
Positive Factors
CDMO business model
A broad CDMO offering (formulation, manufacturing, packaging) builds durable, contract-based revenue and customer stickiness. End-to-end capability across dosage forms supports scale, diversified service income and predictable manufacturing revenue over the next 2-6 months and beyond.
Negative Factors
Slowing revenue growth
Revenue growth decelerated sharply, which can constrain scale benefits and slow margin expansion. If top-line momentum stalls, the company may face tougher competition to win new contracts, reducing headroom for sustainable profit and cash-flow improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO business model
A broad CDMO offering (formulation, manufacturing, packaging) builds durable, contract-based revenue and customer stickiness. End-to-end capability across dosage forms supports scale, diversified service income and predictable manufacturing revenue over the next 2-6 months and beyond.
Read all positive factors
Akums Drugs and Pharmaceuticals Limited (AKUMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹74.74B
Dividend YieldN/A
Average Volume (3M)11.50K
Price to Earnings (P/E)26.2
Beta (1Y)1.32
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees7,536
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.33
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.32
Price to Sales (P/S)1.74
P/FCF Ratio36.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹680.00Price Target Upside61.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)17.72
Revenue Forecast (FY)₹42.98B
Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary su...
How the Company Makes Money
AKUMS makes money mainly by providing contract manufacturing and related development services to pharmaceutical and healthcare companies that market products under their own brands. Its core revenue stream is manufacturing fees embedded in the sal...
Akums Drugs and Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
65
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.26B | 40.71B | 40.20B | 34.75B | 36.47B |
| Gross Profit | 7.62B | 16.05B | 14.37B | 11.67B | 12.69B |
| EBITDA | 2.39B | 5.29B | 1.31B | 3.09B | -821.80M |
| Net Income | 1.88B | 3.38B | -40.35M | 948.55M | -2.53B |
Balance Sheet | |||||
| Total Assets | 51.59B | 41.13B | 35.16B | 32.67B | 30.69B |
| Cash, Cash Equivalents and Short-Term Investments | 16.78B | 5.82B | 2.88B | 1.50B | 1.03B |
| Total Debt | 902.87M | 882.12M | 5.65B | 6.19B | 3.95B |
| Total Liabilities | 19.91B | 10.50B | 27.96B | 25.43B | 24.44B |
| Stockholders Equity | 31.49B | 30.47B | 7.09B | 7.17B | 6.22B |
Cash Flow | |||||
| Free Cash Flow | 13.13B | 1.93B | 1.87B | -1.52B | -2.26B |
| Operating Cash Flow | 15.47B | 4.65B | 4.98B | 1.77B | 318.54M |
| Investing Cash Flow | -12.71B | -5.48B | -3.30B | -3.05B | -2.35B |
| Financing Cash Flow | -5.29B | 727.88M | -1.08B | 1.25B | 2.36B |
Akums Drugs and Pharmaceuticals Limited Technical Analysis
Neutral
420.10
Price Trends
464.08
Positive
450.27
Positive
476.62
Negative
Market Momentum
2.87
Positive
49.70
Neutral
59.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Neutral. The current price of 420.1 is below the 20-day moving average (MA) of 480.35, below the 50-day MA of 464.08, and below the 200-day MA of 476.62, indicating a neutral trend. The MACD of 2.87 indicates Positive momentum. The RSI at 49.70 is Neutral, neither overbought nor oversold. The STOCH value of 59.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AKUMS.
Akums Drugs and Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹35.28B | 25.06 | ― | 0.96% | 6.51% | 18.24% | |
64 Neutral | ₹8.06B | 12.53 | ― | ― | 8.92% | -5.56% | |
63 Neutral | ₹74.74B | 26.19 | ― | ― | ― | ― | |
58 Neutral | ₹2.68B | 48.53 | ― | ― | -0.77% | 2055.99% | |
58 Neutral | ₹1.05B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
57 Neutral | ₹5.48B | 19.44 | ― | 1.96% | -6.96% | -66.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
474.85
3.80
0.81%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
113.45
34.70
44.06%
IN:BALPHARMA
Bal Pharma Limited
65.86
-22.14
-25.16%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
384.85
-3.38
-0.87%
IN:KOPRAN
Kopran Limited
113.50
-70.21
-38.22%
IN:WANBURY
Wanbury Limited
230.70
-38.20
-14.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.